Extended Data Fig. 4: Cellular phenotyping of COVID-19 patients with cancer.
From: CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
a, Frequencies of circulating T follicular helper cells (cTfh), plasmablasts (No Cancer vs. Heme, p = 0.0001; Solid vs. Heme, p = 0.006), and CD138 expression on plasmablasts (HD n = 33; non-cancer n = 108; solid cancer n = 7; heme cancer n = 3). b, UMAP projection of non-naïve CD8 T cells with indicated protein expression. c, Heatmap showing expression patterns of various markers, stratified by FlowSOM clusters. Heat scale calculated as column z-score of MFI. d, Frequencies of CD8 subsets: naive (CD45RA+ CD27+ CCR7+), central memory (CD45RA-CD27+ CCR7+), transition memory (CD45RA-CD27+ CCR7-) (p < 0.0001), effector memory (CD45RA-CD27-CCR7-), and TEMRA (CD45RA+ CD27-CCR7-) (p = 0.002) (HD n = 33; non-cancer n = 108; cancer n = 9). e, (Left) HLA-DR and CD38 co-expression in concatenated activated clusters (3, 4, and 5) and associated UMAP localization. (Right) Frequency of clusters 3 (p = 0.03) and 5 (HD n = 30; non-cancer n = 110; cancer n = 8). (All) Significance determined by two-sided Mann Whitney test: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Median and 95% CI shown.
